Format

Send to

Choose Destination
See comment in PubMed Commons below
Antimicrob Agents Chemother. 2012 Jun;56(6):3448-52. doi: 10.1128/AAC.06257-11. Epub 2012 Mar 5.

Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.

Author information

1
Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA. dsnydman@tuftsmedicalcenter.org

Abstract

We evaluated the activity of CB-183,315 against Clostridium difficile, including strains that are resistant to fluoroquinolones and metronidazole and with elevated MICs to vancomycin as well as other Gram-positive intestinal pathogens. The MICs of CB-183,315 against all C. difficile isolates were ≤ 1 μg/ml. CB-183,315 had greater activity than vancomycin and metronidazole against C. difficile isolates and was more active than the comparators against vancomycin-resistant enterococcus (VRE). CB-183,315 also had excellent activity against methicillin-resistant Staphylococcus aureus (MRSA), other Clostridium spp., and Peptostreptococcus spp.

PMID:
22391542
PMCID:
PMC3370783
DOI:
10.1128/AAC.06257-11
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center